Replies to post #156616 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Their combo only works if there was prior t-cell infiltration into the tumor. DCVax-l’s mechanism of action causes a full spectrum of t-cell infiltration. Stanford’s therapy is not targeted, but NWBO’s is multi targeted. Consequently, one could imagine trying the three together one day. I did not say the Stanford therapy was as good or better than DCVax-L.

[Sojourner55]

"So… targeting one antigen or protein and getting rid of it is a good thing. The problem is, though, that if there are other targets on the cancer that the treatment doesn’t target, what good is that?"

Exactly, cancer is complex and diverse so do you use a sniper vs a shotgun approach as DCVAX. A targeted approach is limited and probably effective in a smaller subset of cancers as the CAR-Ts. The DCVAX platform will revolutionize cancer treatment, nothing is more personalized, natural and broad spectrum mode of action. A powerful concept the lay person can understand.

GO NWBO!

[jondoeuk]

CpG targets pDCs and the anti-OX40 mAb (this will be given via IV and they are using the drug produced by $BMY) on both effector and regulatory T-cells. The trial will in patients with a range of low-Grade B-cell non-Hodgkin lymphomas. Before the intratumoral injections of SD-101 they will use low-dose radiotherapy to cause immunogenic cancer cell death.

These types of cancer have a lower mutational burden. However the immune system can mount a response and it just targets the cancer cells and not the healthy B-cells https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954133/

I know Dr. Brody will be testing intratumoral FLT3L http://www.cell.com/cancer-cell/fulltext/S1535-6108(14)00370-5 http://www.cell.com/immunity/fulltext/S1074-7613(16)30101-7 http://jem.rupress.org/content/184/5/1953.long to increase certain DC subsets within the tumour, low-dose radiotherapy and a TLR3 agonist (Poly-ICLC) in a range of solid cancers. This will also be combined with a systemic PD-1 inhibitor.